Navigation Links
Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
Date:12/21/2007

MALVERN, Pa., Dec. 21 /PRNewswire/ -- Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith as President and Chief Executive Officer. He will also continue to serve as Chairman to its Board of Directors.

Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance, leadership, and strategies for growth as the company continues to broaden its product portfolio globally and map its strategy.

Mr. Smith has nearly 35 years of broad and global experience in the pharmaceutical industry and most recently served as President and Chief Executive Officer of INO Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combinations. Prior to INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company, where he served as President of U.S. Operations, Executive Vice President of Europe, and Vice President and General Manager in Canada, among numerous other positions at DuPont Pharmaceuticals and DuPont Merck. Mr. Smith was also employed in management positions at Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is a graduate of Michigan State University and the Lake Forest Graduate School of Business.

"I am excited to be joining Solstice at this time to work with the management team and the Board of Directors to help lead and guide our company's future strategic direction," said Mr. Smith.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, Myobloc(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com.

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
2. Insmed Appoints Dennis M. Lanfear to Board Of Directors
3. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
4. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
5. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
6. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
7. KGI and Smith College Establish Leadership Forum for Women in Bioscience
8. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
9. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
10. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
11. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... -- There is no saying when exactly ... pressures in pricing and lack in consumer confidence. One ... - numerous opportunities are up for grabs but this ... four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels (TCA) today ... Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. , ... of ACA’s member angel groups. It is the highest honor available for an early-stage ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, ... result of asthma complications.* Costing more than $56 billion in direct costs annually, ... , “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly ...
(Date:5/17/2016)... Texas (PRWEB) , ... May 17, 2016 , ... ... for use in animal waste reduction applications, announced today it will be showcasing ... Moines, Iowa. , ManureMagic™ was featured in the Wall Street Journal last year ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):